Diagnósticos da América (DASA3) Q3 2024 earnings summary

Executive summary

• Achieved operational efficiency and productivity gains, with international recognition for hospital excellence and sustainability.

• Operational excellence and restructuring led to best NPS ratings and significant financial improvements.

• Strategic focus included margin optimization, sale of Dasa Empresas, and progress on the Amil joint venture.

• Ongoing process revisions and organizational restructuring to align with core business and optimize G&A.

• Net income loss narrowed by 52% year-over-year, mainly due to EBITDA growth; excluding FX effects, net result would be near zero.

Financial highlights

• Gross revenue rose 6% year-over-year to R$4.3 billion, with both Hospitals & Oncology and Diagnostics contributing.

• Adjusted EBITDA grew 14% year-over-year to R$751 million, with margin up 1.4 p.p. to 18.9%.

• Adjusted expenses reduced by 12% year-over-year, reflecting operational excellence.

• Investments totaled R$137 million, a 19% reduction year-over-year, focused on high-return and technology projects.

• Cash and equivalents at R$2.8 billion, covering 1.4x–1.5x debts due by end-2025.

Outlook and guidance

• Continued focus on core businesses, margin improvement, and G&A optimization, with non-core asset divestitures ongoing.

• Investment budget for 2024 set at R$565 million, a 22% reduction from 2023.

• Expectation of further deleveraging and improved capital structure by next year.